Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory

Stephen Ayers9.6K FollowersFollow5ShareSavePlay(11min)CommentsSummaryIntellia Therapeutics remains a 'Sell' despite the FDA lifting the clinical hold on its ATTR-CM program due to persistent commercial and safety concerns.NTLA faces a crowded competitive landscape in both ATTR and HAE, with limited patient willingness to adopt one-time gene edits over established treatments.High cash burn (~$400M/year) and likely dilution threaten NTLA's runway, with profitability hinging on successful HAE market penetration.I model low uptake and negative NPV for ATTR-CM, while HAE offers some promise but faces significant adoption and safety hurdles. demaerre/iStock via Getty Images Overview Intellia Therapeutics’ stock (NTLA) is flat since my “Sell” rating earlier this year. This is a company advancing its in vivo gene therapies: mainly for ATTR and HAE. I’ve expressed caution in the past. BothThis article was written byStephen Ayers9.6K FollowersFollowRN/MBA with a focus on Biotech, Pharma, and Tech sectors.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. Financial models presented here, including DCF, rNPV, and scenario analyses, are illustrative tools based on the author's assumptions and are highly sensitive to inputs; small changes can materially alter outputs. The predictions and opinions presented reflect a probabilistic approach, not absolute certainty. Efforts have been made to ensure accuracy, but inadvertent errors may occur. Readers are advised to independently verify information and conduct their own research. Investing in stocks involves inherent volatility and risk. Before making any investment decisions, it is crucial for readers to conduct thorough research and assess their financial circumstances. The author is not liable for any financial losses incurred as a result of using or relying on the content of this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.